This Edition
ARTICLE | Emerging Company Profile
WindMIL: T cell source is key
WindMIL is harnessing marrow-derived T cells to develop cell therapies for cancer
Elizabeth S. Eaton, Staff Writer
February 26, 2020 9:26 PM UTC
Access this Article
Request a Trial
Purchase This Article
Log in
BCIQ Company Profiles
WindMIL Therapeutics Inc.
BCIQ Company Profiles
WindMIL Therapeutics Inc.